| Objective Researching on epidermal growth factor receptor (EGFR) mutations withmultiple pathways specimens in advanced non-small cell lung cancer (aNSCLC)patients,and studying the relationship between EGFR mutation and specimensource,clinical features,pathological features,stage, the value of serum serumcarcinoembryonic antigen (CEA).Methods Collected multiple pathways specimens like tumor tissue,malignant pleural effusion and plasma in NSCLC patients.Used QIAamp CirculatingNucleic Acid Kit to extract cfDNA in plasma,used scorpion probe amplificationrefractory mutation system (sARMS) for EGFR mutation test.Results1. The EGFR mutation rate of103cases in patients with NSCLC used tissue ormalignant pleural effusion specimens was48.5%(50/103),There was a significantcorrelation between EGFR mutation smoking history and histological type (P<0.05).Nocorrelation with gender,age, physical status score, stage and the value of serum CEA.2. The mutation rate of metastases source group（58.6%）was higher than the primarytumor source group (35.6%). Patients with malignant pleural effusions (67.5%) washigher than those without pleural effusion (36.5%)(P <0.05).3. Verses tissue or malignant pleural effusion specimens,the EGFR mutation positiverate in29cases of paired plasma samples was37.9%（11/29）, sensitivity was43.7%（7/16）and specificity was69.2%（9/13）. Conclusion1.NSCLC patients with EGFR gene mutation usually observe in non-smoking andadenocarcinoma patients.There is no significant difference with gender,serumcarcinoembryonic antigen,clinical stage and physical status.2.The EGFR mutation rate is higher in patients with malignant pleural effusion thanpatients without.3.Using QIAamp Circulating Nucleic Acid Kit for extracting cfDNA in plasma to detectEGFR mutation,the sensitivity is acceptable. Plasma may be a complementary approachfor tumor tissue.4.Due to the existence of intratumoral EGFR mutational heterogeneity, obtainingdifferent parts of the tumor tissue is essential. |
PDF Full Text Request